Oral transmucosal fentanyl citrate for the treatment of breakthrough pain

被引：0
|
作者：
Zarth, R.
Ehmer, M.
Sittig, H. -B.
机构：
[1] Univ Tubingen, Akad Lehrkrankenhaus, Zollernalb Klinikum, Anaesthesiol & Intens Med Abt, D-72336 Balingen, Germany
[2] Praxis Schemerztherapie & Palliativ Med, Freiburg, Germany
[3] Spezielle Schmerztherapie Palliativ Med, MVZ Buntenskamp, Geesthacht, Germany
来源：
SCHMERZ | 2007年 / 21卷 / 06期
关键词：
cancer-related pain; breakthrough pain; oral transmucosal fentanyl citrate; observational study;
D O I：
10.1007/s00482-007-0590-z
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
In a non-interventional study the efficacy and tolerability of oral transmucosal fentanyl citrate (OTFC) was studied in patients with opioid-treated cancer pain suffering from breakthrough pain. The prospective multicenter observational trial included 406 patients. For 3-4 months, efficacy of OTFC treatment for breakthrough pain was documented using a numerical analog pain intensity scale (NAS). Further, OTFC therapy was rated and adverse events were recorded. With application of oral transmucosal fentanyl citrate median pain intensity fell from NAS 8 points at the beginning to NAS 2 points at the end of the study. The median effective dosage was 400 g. Tolerability was rated as good or very good by 87.5% of the patients. Oral transmucosal fentanyl citrate is a safe and effective treatment for breakthrough pain in chronic cancer-related pain.
引用
收藏
页码：545 / 552
页数：8
相关论文
共 50 条
  • [31] Oral transmucosal fentanyl: Evaluation of medical and nursing practices
    Combe, Claire
    Bourne, Cindy
    Chiganne, Marie
    Geneste, Marie
    Hida, Hassan
    Lacroix, Catherine
    MEDECINE PALLIATIVE, 2014, 13 (02): : 77 - 83
  • [32] Intranasal Fentanyl for Breakthrough Pain Control
    Clavijo, Claudia F.
    Lynn, Rachael Rzasa
    Christians, Uwe
    Galinkin, Jeffrey L.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2012, 4 : 241 - 250
  • [33] Breakthrough pain treatment with sublingual fentanyl in patients with chronic cutaneous ulcers
    Domingo-Triado, V.
    Lopez Alarcon, M. D.
    Villegas Estevez, F.
    Alba Moratillas, C.
    Massa Dominguez, B.
    Palomares Paya, F.
    Minguez Marti, A.
    Debon Vicent, L.
    REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION, 2014, 61 (08): : 429 - 433
  • [34] The treatment of breakthrough pain
    McCarberg, Bill H.
    PAIN MEDICINE, 2007, 8 : S8 - S13
  • [35] Breakthrough Pain: Focus on Fentanyl Buccal Tablet
    Lecybyl, Remigiusz
    Hanna, Magdi
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2010, 2 : 89 - 98
  • [36] Pre-hospital oral transmucosal fentanyl citrate for trauma analgesia: preliminary experience and implications for civilian mass casualty response
    Carenzo, Luca
    McDonald, Adam
    Grier, Gareth
    BRITISH JOURNAL OF ANAESTHESIA, 2022, 128 (02) : E206 - E208
  • [37] Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain
    Darba, Josep
    Kaskens, Lisette
    Sanchez-de la Rosa, Rainel
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2014, 6 : 1 - 9
  • [38] Fentanyl buccal tablet for the treatment of breakthrough pain in systemic mastocytosis - a case study
    Zasowska-Nowak, Anna
    Cialkowska-Rysz, Aleksandra
    MEDYCYNA PALIATYWNA-PALLIATIVE MEDICINE, 2020, 12 (04): : 216 - 221
  • [39] The FARADI study: the efficacy and safety of fentanyl citrate in breakthrough pain induced by diagnostic examinations or treatments in patients with cancer
    Labreze, L.
    Pulido, M.
    Krakowski, I.
    ONCOLOGIE, 2017, 19 (1-2) : 26 - 31
  • [40] Efficacy of Sublingual Fentanyl vs. Oral Morphine for Cancer-Related Breakthrough Pain
    Ignacio Velázquez Rivera
    José Carlos Muñoz Garrido
    Pilar García Velasco
    Inmaculada España Ximénez de Enciso
    Lourdes Velázquez Clavarana
    Advances in Therapy, 2014, 31 : 107 - 117
12345